{
    "organizations": [],
    "uuid": "459fb4d1721e352826826e970df724681b666230",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-antibe-announces-enrollment-in-mid/brief-antibe-announces-enrollment-in-mid-stage-trial-of-pain-drug-atb-346-idUSFWN1PO0QC",
    "ord_in_thread": 0,
    "title": "BRIEF-Antibe Announces Enrollment In Mid-Stage Trial of Pain Drug ATB-346",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 29 (Reuters) - Antibe Therapeutics Inc:\n* ANTIBE THERAPEUTICS ANNOUNCES ENROLLMENT OF FINAL SUBJECTS IN PHASE 2B GASTROINTESTINAL SAFETY STUDY OF LEAD PAIN DRUG, ATB-346 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-29T20:08:00.000+02:00",
    "crawled": "2018-01-30T18:48:21.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "antibe",
        "therapeutic",
        "inc",
        "antibe",
        "therapeutic",
        "announces",
        "enrollment",
        "final",
        "subject",
        "phase",
        "2b",
        "gastrointestinal",
        "safety",
        "study",
        "lead",
        "pain",
        "drug",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}